Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors

by Nirmitha I. Herath, Nirmitha I. Herath, Nirmitha I. Herath, Nirmitha I. Herath, Nathalie Berthault, Nathalie Berthault, Sylvain Thierry, Sylvain Thierry, Wael Jdey, Wael Jdey, Wael Jdey, Wael Jdey, Marie-Christine Lienafa, Marie-Christine Lienafa, Françoise Bono, Patricia Noguiez-Hellin, Jian-Sheng Sun, Marie Dutreix, Marie Dutreix
Published 2019-11-01

AsiDNA Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance

by Wael Jdey, Maria Kozlak, Sergey Alekseev, Sylvain Thierry, Pauline Lascaux, Pierre-Marie Girard, Françoise Bono, Marie Dutreix
Published 2019-09-01

Evolution of tumor cells during AsiDNA treatment results in energy exhaustion, decrease in responsiveness to signal, and higher sensitivity to the drug

by Pierre‐Marie Girard, Nathalie Berthault, Maria Kozlac, Sofia Ferreira, Wael Jdey, Srividya Bhaskara, Sergey Alekseev, Frederic Thomas, Marie Dutreix
Published 2020-08-01

A Preclinical Study Combining the DNA Repair Inhibitor Dbait with Radiotherapy for the Treatment of Melanoma

by Julian Biau, Flavien Devun, Wael Jdey, Ewa Kotula, Maria Quanz, Emmanuel Chautard, Mano Sayarath, Jian-Sheng Sun, Pierre Verrelle, Marie Dutreix
Published 2014-10-01